In testimony presented today at the U.S. Federal Drug Administration’s (FDA) public hearing on ways to advance development of drugs, vaccines and other medical products used in the prevention, treatment, and diagnosis of neglected tropical diseases (NTDs), Sabin President Dr. Peter Hotez advised the agency to help product development partnerships (PDP) navigate the bureaucratic and economic barriers which delay development and distribution of treatments to affected populations.

“The FDA can help enormously by increasing its guidance and mentorship to PDPs to help them meet the needs of national regulatory authorities and the FDA as well as finding ways to operationalize more efficiently,” said Dr. Hotez.